ArticleScience advances2020
Peptidoglycan editing provides immunity to
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 61 citations in OpenAlex.
- Engineering the probioticSynthetic and systems biotechnology · 2026Article
- Therapeutic significance of surface-exposed virulence factors in Acinetobacter baumannii pathogenicity.Molecular biology reports · 2026Review
- Article
- Periplasmic crowding and peptidoglycan hydrolase activity as drivers of outer membrane vesiculation in Acinetobacter baumannii.Communications biology · 2026Article
- The type VI secretion system of Acinetobacter: mechanisms, biology and therapeutic potential.Communications biology · 2026Review
- Chiral peptidoglycan mimics target bacterial wall biosynthesis for pathogen intervention.Nature communications · 2026Article
- A widely-occurring family of pore-forming effectors broadens the impact of the Serratia Type VI secretion system.The EMBO journal · 2025Article
- MutantMicrobiology spectrum · 2025Article
- The interplay betweenInfection and immunity · 2025Article
- Thioredoxin 1 moonlights as a chaperone for an interbacterial ADP-ribosyltransferase toxin.Nature communications · 2024Article
- Mechanisms conferring bacterial cell wall variability and adaptivity.Biochemical Society transactions · 2024Review
- Article
- T6SS nuclease effectors inJournal of bacteriology · 2024Article
- Mechanisms of bacterial immunity, protection, and survival during interbacterial warfare.Cell host & microbe · 2024Review
- Identification of type VI secretion system effector-immunity pairs using structural bioinformatics.Molecular systems biology · 2024Article
- Supercharged precision killers: Genetically engineered biomimetic drugs of screened metalloantibiotics againstScience advances · 2024Article
- Defense and anti-defense mechanisms of bacteria and bacteriophages.Journal of Zhejiang University. Science. B · 2024Article
- Article
- Value of T6SS Core GeneIndian journal of microbiology · 2023Article
- A subcellular biochemical model for T6SS dynamics reveals winning competitive strategies.PNAS nexus · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 4 countries.
Funding
Abstract
Peptidoglycan (PG) is essential in most bacteria. Thus, it is often targeted by various assaults, including interbacterial attacks via the type VI secretion system (T6SS). Here, we report that the Gram-negative bacterium
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.